Magnesium Threonate

ApprovedSmall molecule

UUniversity of Miami

Magnesium Threonate is one of 7 small molecule programs targeting Sleep. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SleepRecruiting

SleepApproved

Recruiting

Competition

Competitive Landscape

7 competitors in Sleep

#DrugCompanyPhaseTrials

Ambien

PPurdue Pharma LP

Approved

4 2

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

2 3

Imovane

TTaisho Pharmaceutical Co., Ltd.

Phase 3

1 4

Dayvigo

Eisai

Phase 2

2 5

Belsomra

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 6

Magnesium Threonate

UUniversity of Miami

Approved

1 7

Ketalar

Boehringer Ingelheim

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

ApprovedRecruiting

Sleep

NCT06902285

Clinical

Trials by Indication[1]

Sleep1 trial

Use of Magnesium-L-Threonate to Improve Subjective Sleep Quality After Total Joint Arthroplasties: Randomized Controlled Clinical Trial

Recruiting·UUniversity of Miami·Approved·NCT06902285·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Magnesium Threonate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Magnesium Threonate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Magnesium Threonate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Miami company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Miami

Magnesium Threonate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Sleep1 trial

References

Drug Info

Quick Facts

Related News